Nicotinell Support Icemint (Nicotine Polacrilex)

Nicotine polacrilex releases nicotine in the mouth, where it is absorbed through the buccal lining. The nicotine then binds to nicotinic acetylcholine receptors in the brain, partially stimulating the same pathways activated by cigarette smoking. This mimics the nicotine effect, easing withdrawal and cravings while allowing the user to taper their nicotine intake.

The specific dose and duration of Nicotinell Support Icemint are determined by the prescribing healthcare professional based on the individual’s smoking history, nicotine dependence level, and overall health. Patients should follow the prescriber’s instructions and not alter the dosing regimen without medical advice.

Safety data for nicotine polacrilex in pregnancy and lactation are limited. Because nicotine can cross the placenta and enter breast milk, the product should only be used during pregnancy or while breastfeeding if the potential benefits outweigh the risks and after consulting a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Nicotinell Support Icemint delivers nicotine via a buccal tablet, offering a discreet, non‑combustible alternative to patches, gums, or lozenges. Compared with patches, it provides faster onset of action; versus gum, it may cause less oral irritation for some users. Choice depends on personal preference, dosing flexibility, and tolerance of side effects.

Store the product at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the tablets out of reach of children and avoid exposing them to extreme heat or humidity, which could affect the integrity of the nicotine polacrilex matrix.

The tablet is placed between the gum and cheek (buccal cavity) and allowed to dissolve slowly. Do not chew or swallow the tablet whole. The user should keep the tablet in place until it fully dissolves, typically a few minutes, to ensure optimal nicotine absorption through the buccal mucosa.

Serious risks, though rare, include allergic reactions such as rash, swelling, or difficulty breathing, and cardiovascular events like chest pain or irregular heartbeat, especially in individuals with pre‑existing heart disease. Users should seek immediate medical attention if they experience any signs of a severe allergic response or cardiac symptoms.

The product is contraindicated for non‑smokers, individuals who are not nicotine‑dependent, and those with recent myocardial infarction, unstable angina, or severe cardiovascular disease unless cleared by a physician. Children and pregnant or breastfeeding women should only use it under direct medical supervision.